DHRS3 Antibody

What is DHRS3 and what is its biological function?

DHRS3 (Dehydrogenase/reductase SDR family member 3), also known as retSDR1 or DD83.1, belongs to the short-chain dehydrogenases/reductases (SDR) family. The protein primarily catalyzes the reduction of all-trans-retinal to all-trans-retinol in the presence of NADPH, playing a crucial role in retinoid metabolism .

Expression studies have revealed high levels of DHRS3 in fetal kidney, liver, and lung tissues, as well as in adult heart, placenta, lung, liver, kidney, pancreas, thyroid, testis, stomach, trachea, and spinal cord. Lower expression levels are observed in skeletal muscle, intestine, and lymph node, while the protein is barely detectable in adrenals, brain, and thymus .

What applications can DHRS3 antibodies be used for?

DHRS3 antibodies are versatile tools that can be employed in multiple experimental techniques:

For optimal results, researchers should titrate antibodies in their specific testing systems, as performance may be sample-dependent .

What are the observed physical properties of DHRS3 protein?

The physical characteristics of DHRS3 are important for experimental design and validation:

• Calculated molecular weight: 34 kDa

• Observed molecular weight range: 30-34 kDa

• GenBank Accession Number: BC002730

• Gene ID (NCBI): 9249

• UniProt ID: O75911

In vitro transcription-translation assays using rat liver DHRS3 cDNA have produced two major protein bands of approximately 30 and 35 kDa, consistent with the observed molecular weight in tissue samples .

How should researchers optimize storage and handling of DHRS3 antibodies?

For maximum antibody stability and performance:

• Store DHRS3 antibodies at -20°C in their recommended buffer systems (typically PBS with 0.02% sodium azide and 50% glycerol, pH 7.3)

• Antibodies are generally stable for one year after shipment when stored properly

• For many formulations, aliquoting is unnecessary for -20°C storage

• Some antibody preparations (typically smaller 20μl sizes) may contain 0.1% BSA as a stabilizer

• When working with antibodies containing sodium azide, handle with appropriate precautions as it is a hazardous substance

This methodological approach to storage ensures reproducible results across experiments and maximizes the usable lifespan of the antibody reagents.

What experimental factors affect DHRS3 expression and regulation?

DHRS3 expression is dynamically regulated by several factors:

• Retinoic acid (RA): DHRS3 mRNA increases 30- to 40-fold after treatment with ≤20 nM RA for 24 hours. Among synthetic retinoids tested, only Am580 (a RA receptor-α-selective retinoid) shows similar effects on expression .

• Inflammatory stimuli: In rat models, DHRS3 mRNA was doubled by RA treatment but reduced by >90% after treatment with LPS (lipopolysaccharide), both alone and in combination with RA .

• DNA methylation: Hypermethylation of the DHRS3 gene promoter results in decreased gene expression in gastric cancer tissues. Treatment with 5'-Aza (a DNA methylation inhibitor) restores DHRS3 expression in cancer cell lines .

These regulatory mechanisms should be considered when designing experiments to study DHRS3 function or when using it as a biomarker.

How can researchers validate DHRS3 antibody specificity?

A comprehensive validation strategy should include:

• Positive control tissues/cells: Use known DHRS3-expressing samples such as HepG2 cells, HEK-293 cells, mouse liver tissue, or A375 cells as positive controls .

• Knockout/knockdown validation: Multiple publications have utilized DHRS3 knockdown models for antibody validation .

• Western blot analysis: Confirm the presence of bands at the expected molecular weight (30-34 kDa) .

• Immunogen specificity: When available, use recombinant DHRS3 protein or fusion proteins as positive controls .

• Cross-reactivity testing: Examine reactivity across species (human, mouse, rat) when using the antibody for comparative studies .

It's recommended to include appropriate controls in each experiment, particularly when working with new tissue types or experimental conditions.

What methodological approaches can be used to study DHRS3's role in cancer?

Based on recent findings about DHRS3's tumor suppressor function in gastric cancer, several experimental approaches are recommended:

• Methylation analysis: Examine DHRS3 promoter methylation using bisulfite-assisted techniques to assess epigenetic silencing in tumor samples .

• Expression profiling: Compare DHRS3 mRNA and protein levels between tumor and adjacent normal tissues using qPCR and immunohistochemistry. In gastric cancer studies, 82.9% of normal tissues showed strong DHRS3 staining while most cancer samples were weakly stained (38.6%) or negative (41.4%) .

• Functional studies: Use lentiviral expression systems to restore DHRS3 expression in cancer cell lines (e.g., MKN28 cells) and examine effects on:

  • Cell proliferation (MTT assay)

  • Colony formation

  • Migration (scratch wound healing assay)

  • Cell cycle progression and apoptosis (flow cytometry)

  • In vivo tumor growth in nude mice models

• Clinicopathological correlation: Analyze the relationship between DHRS3 expression/methylation and clinical parameters including histological type, differentiation, tumor stage, and patient age .

These approaches provide a comprehensive framework for investigating DHRS3's functional role in cancer progression and its potential as a biomarker or therapeutic target.

How does DHRS3 interact with other proteins in retinoid metabolism pathways?

Recent research has revealed a complex interplay between DHRS3 and other retinoid metabolism enzymes:

• Mutual activation with RDH10: DHRS3 requires RDH10 for full enzymatic activity and, in turn, activates RDH10. This mutually activating relationship allows for precise control over retinoic acid biosynthesis .

• Experimental approaches to study interactions:

  • Co-immunoprecipitation using anti-DHRS3 antibodies

  • Western blot analysis after treatment with retinoic acid

  • Enzymatic activity assays measuring the conversion of retinaldehyde to retinol

  • Expression analysis in response to retinoid treatment

• Functional consequences: The interaction between DHRS3 and RDH10 represents a previously unrecognized regulatory mechanism that may be conserved across species and is critical for controlling local concentrations of retinoic acid during development and in adult tissues .

Understanding these protein-protein interactions is essential for a comprehensive view of retinoid metabolism and may provide insights into developmental disorders and diseases associated with retinoid signaling dysregulation.

What are the best methodological approaches for using DHRS3 antibodies in multi-label immunofluorescence studies?

For successful multi-label immunofluorescence experiments with DHRS3 antibodies:

• Antibody selection: Choose antibodies raised in different host species to avoid cross-reactivity. For DHRS3, rabbit polyclonal antibodies are common, so pair with mouse, goat, or rat antibodies for other targets .

• Optimal dilutions: For immunofluorescence/ICC applications:

  • Rabbit polyclonal antibody 83581-3-RR: 1:50-1:500

  • Rabbit polyclonal antibody ab236603: 1:100

  • Rabbit polyclonal antibody 15393-1-AP: 1:200-1:800

• Cell selection: HepG2 cells have been validated for DHRS3 immunofluorescence studies with multiple antibodies .

• Antigen retrieval methods: For tissue sections, use TE buffer pH 9.0 or alternatively citrate buffer pH 6.0 for optimal DHRS3 detection .

• Visualization systems: Secondary antibodies such as Alexa Fluor® 488-conjugated Goat Anti-Rabbit IgG (H+L) have been validated for DHRS3 detection .

This methodological framework ensures specific detection and minimizes background in multi-label immunofluorescence studies targeting DHRS3 alongside other proteins of interest.

How can researchers use DHRS3 antibodies to investigate its potential tumor suppressor role?

Based on evidence of DHRS3's tumor suppressor function, particularly in gastric cancer, researchers can employ the following methodological approaches:

• Expression analysis across cancer types:

  • Use immunohistochemistry with DHRS3 antibodies (recommended dilutions 1:50-1:500) to examine expression patterns in tumor vs. normal tissues

  • Quantify staining intensity using established scoring systems (e.g., negative, weak, moderate, strong)

• Mechanistic studies:

  • Examine cell cycle effects using flow cytometry (DHRS3 overexpression results in G1 phase arrest)

  • Assess apoptosis induction (DHRS3 induces early apoptosis)

  • Analyze effects on migration using scratch assays or transwell systems

• Correlation with clinicopathological features:

  • Analyze relationships between DHRS3 expression/methylation and histological type, differentiation, tumor stage

  • Data shows significant correlation between DHRS3 hypermethylation and histological type (p<0.05) and poor differentiation (p<0.05) in gastric cancer

• Molecular pathway analysis:

  • Use DHRS3 antibodies in combination with other pathway-specific antibodies to determine involvement in retinoid signaling and other potentially related pathways

  • Perform Western blot analysis after modulating DHRS3 expression to identify downstream effectors

These approaches provide a comprehensive framework for investigating DHRS3's functional significance in cancer biology and may inform the development of new diagnostic or therapeutic strategies.